Placental Cells for Diabetic Foot Ulcers
30 juni 2026 bijgewerkt door: Wake Forest University Health Sciences
Phase 1 Safety Trial of Placental Stem Cells (PLSC) to Accelerate the Healing of Diabetic Foot Ulcers
The purpose of this research study is to test the safety of placental stem cells to treat non-healing diabetic foot ulcers.
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a prospective, non-randomized, single institution, Phase 1 safety trial to evaluate the safety of placental stem cells and the rate of diabetic foot ulcer healing in a population of subjects with non-healing diabetic foot ulcers for at least 4 weeks.
The trial will also explore the clinical outcomes of placental stem cells treatment on diabetic peripheral neuropathy.
Furthermore, the trial will evaluate the effect of the placental stem cells on serum biomarkers associated with diabetic foot ulcers and diabetic peripheral neuropathy (measured pre- and post-treatment) and correlate the biomarker levels with any changes in diabetic foot ulcers and diabetic peripheral neuropathy.
Twelve adult subjects with non-healing diabetic foot ulcers for at least four weeks from diagnosis and not more than 12 months with wound sizes ≥ 2 cm2 and ≤ 4 cm2 will be recruited and treated.
Subjects will be followed for 12 months after treatment.
Studietype
Ingrijpend
Inschrijving (Geschat)
12
Fase
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Mary-Clare Day, RN
- Telefoonnummer: 336-713-1343
- E-mail: maryclare.day@advocatehealth.org
Studie Locaties
-
-
North Carolina
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Atrium Health Wake Forest Baptist
-
Contact:
- Mary-Clare Day, RN
- Telefoonnummer: 336-713-1343
- E-mail: maryclare.day@advocatehealth.org
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Diagnosed with Type 2 Diabetes mellitus (DM) - for at least 1 year
- Unilateral non-healing Diabetic Foot Ulcer (DFU) > 2 cm2 and ≤ 4 cm2 (length × width) for at least four weeks despite Atrium Health Wake Forest Baptist standard of care treatment (which can include total contact cast, knee high air cast, and/or compression wrap)
- No new diabetes medication for at least 2 weeks pre-treatment
- Subjects must be willing to avoid steroids for the week prior to procedure day
Exclusion Criteria:
- Clinical signs of active infection requiring systemic antibiotic therapy less than 7 days prior to enrollment.
- Radiographic or clinical evidence of active and untreated osteomyelitis at the target ulcer site. Current use of systemic immunosuppressive therapy, including chronic corticosteroids (equivalent to >10 mg/day prednisone for >14 days).
- Hemoglobin (Hgb) A1C >12.0 at screening or time in range for the blood glucose level (TIR) less than 30%. Hb A1c should not be used for patient with hypoalbuminemia or anemia in the past 3 months and for patients with Chronic Kidney disease stage 4. For patients who have Continuous Glucose Monitor (CGM), instead of Hb A1c, TIR (time in range) less than 30 % will be used.
- Patients who are unable / unwilling to tolerate an effective offloading approach. This includes total contact cast, soft felted cast or knee high fracture boot.
- Current alcohol or substance abuse that, in the opinion of the investigators, would interfere with study participation.
- Active malignancy or malignancy related limb amputation.
- Women that are pregnant or planning to become pregnant during the study.
- Patients with albumin levels less than 3.5 or prealbumin levels less than 18.
- Subjects with any conditions that the clinical Investigator believes may jeopardize the safety of the patient to participate in the trial.
- Severe peripheral arterial disease (PAD) (Ankle-Brachial Index (ABI) less than 0.5) or TCOM (Transcutaneous Oximetry Measurement) less than 40 mmHg.
- TWSB > 30 cm2 (total wound surface burden)
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Diabetic with Foot Ulcer
Type 2 diabetes mellitus with a non-healing (> 4 weeks) unilateral diabetic foot ulcer despite standard of care treatment
|
Injection of 30 M placenta stem cells into/around the diabetic foot ulcer and along the anterior and posterior tibial arteries of the index leg.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Injection Sites Bleeding
Tijdsspanne: Month 1
|
Number of Injection Sites Bleeding
|
Month 1
|
|
Number of Injection Sites Bleeding
Tijdsspanne: Month 3
|
Number of Injection Sites Bleeding
|
Month 3
|
|
Number of Injection Sites Bleeding
Tijdsspanne: Month 6
|
Number of Injection Sites Bleeding
|
Month 6
|
|
Number of Injection Sites Bleeding
Tijdsspanne: Month 12
|
Number of Injection Sites Bleeding
|
Month 12
|
|
Number of Injection Sites infection/inflammation
Tijdsspanne: Month 1
|
Number of Injection Sites infection/inflammation
|
Month 1
|
|
Number of Injection Sites infection/inflammation
Tijdsspanne: Month 3
|
Number of Injection Sites infection/inflammation
|
Month 3
|
|
Number of Injection Sites infection/inflammation
Tijdsspanne: Month 6
|
Number of Injection Sites infection/inflammation
|
Month 6
|
|
Number of Injection Sites infection/inflammation
Tijdsspanne: Month 12
|
Number of Injection Sites infection/inflammation
|
Month 12
|
|
Number of Injection Sites with damage to surrounding tissue
Tijdsspanne: Month 1
|
Number of Injection Sites with damage to surrounding tissue
|
Month 1
|
|
Number of Injection Sites with damage to surrounding tissue
Tijdsspanne: Month 3
|
Number of Injection Sites with damage to surrounding tissue
|
Month 3
|
|
Number of Injection Sites with damage to surrounding tissue
Tijdsspanne: Month 6
|
Number of Injection Sites with damage to surrounding tissue
|
Month 6
|
|
Number of Injection Sites with damage to surrounding tissue
Tijdsspanne: Month 12
|
Number of Injection Sites with damage to surrounding tissue
|
Month 12
|
|
Number of Subjects with pain
Tijdsspanne: Month 1
|
Number of Subjects with pain
|
Month 1
|
|
Number of Subjects with pain
Tijdsspanne: Month 3
|
Number of Subjects with pain
|
Month 3
|
|
Number of Subjects with pain
Tijdsspanne: Month 6
|
Number of Subjects with pain
|
Month 6
|
|
Number of Subjects with pain
Tijdsspanne: Month 12
|
Number of Subjects with pain
|
Month 12
|
|
Number of Subjects with allergic reaction to placental cells
Tijdsspanne: Month 1
|
Number of Subjects with allergic reaction to placental cells
|
Month 1
|
|
Number of Subjects with allergic reaction to placental cells
Tijdsspanne: Month 3
|
Number of Subjects with allergic reaction to placental cells
|
Month 3
|
|
Number of Subjects with allergic reaction to placental cells
Tijdsspanne: Month 6
|
Number of Subjects with allergic reaction to placental cells
|
Month 6
|
|
Number of Subjects with allergic reaction to placental cells
Tijdsspanne: Month 12
|
Number of Subjects with allergic reaction to placental cells
|
Month 12
|
|
Number of Subjects with worsening of wound
Tijdsspanne: Month 1
|
Number of Subjects with worsening of wound
|
Month 1
|
|
Number of Subjects with worsening of wound
Tijdsspanne: Month 3
|
Number of Subjects with worsening of wound
|
Month 3
|
|
Number of Subjects with worsening of wound
Tijdsspanne: Month 6
|
Number of Subjects with worsening of wound
|
Month 6
|
|
Number of Subjects with worsening of wound
Tijdsspanne: Month 12
|
Number of Subjects with worsening of wound
|
Month 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Diabetic Foot Ulcer (DFU) size
Tijdsspanne: Month 12
|
DFU healing in this trial will be assessed by measuring the size of the DFU and plotting open wound size over the 12-month follow-up period.
|
Month 12
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Diabetic Peripheral Neuropathy - Semmes-Weinstein Monofilament and Vibration Test
Tijdsspanne: Months 1, 3, 6 and 12
|
The Semmes-Weinstein Monofilament Test is a diagnostic tool used to assess cutaneous touch and pressure sensation.
By using calibrated nylon strands that buckle at specific forces, clinicians can evaluate peripheral nerve function and reliably detect the loss of protective sensation, primarily caused by conditions like diabetic neuropathy
|
Months 1, 3, 6 and 12
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Onderzoekers
- Hoofdonderzoeker: Lucian G. Vlad, MD, Atrium Health Wake Forest Baptist
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 oktober 2026
Primaire voltooiing (Geschat)
1 december 2028
Studie voltooiing (Geschat)
1 december 2028
Studieregistratiedata
Eerst ingediend
30 juni 2026
Eerst ingediend dat voldeed aan de QC-criteria
30 juni 2026
Eerst geplaatst (Werkelijk)
7 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
7 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
30 juni 2026
Laatst geverifieerd
1 juni 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IRB00152562
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Ja
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .